Yarrow Bioscience (YARW) Total Non-Current Liabilities (2016 - 2024)
Yarrow Bioscience's (YARW) quarterly Total Non-Current Liabilities came in at $25000.0 in Q2 2024, down 99.61% YoY from $6.4 million in Q3 2023, and down 98.18% on a QoQ basis from $1.4 million in Q1 2024.
Yarrow Bioscience (YARW) Total Non-Current Liabilities (2016 - 2024) Analysis & Trends
Yarrow Bioscience (YARW) has 8 years of Total Non-Current Liabilities data on file, last reported at $25000.0 in Q2 2024.
- Quarterly Total Non-Current Liabilities fell 99.61% year-over-year to $25000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $25000.0 (down 99.61% YoY) and the FY2023 annual result came in at $1.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities retreated to $25000.0 in Q2 2024, from $1.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $58.6 million in Q2 2021 to a low of $25000.0 in Q2 2024.
- A 4-year average of $23.0 million and a median of $22.0 million in 2021 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities soared 67.15% — and 2024, when it tumbled 99.61%.
- Tracing YARW's Total Non-Current Liabilities over 4 years: stood at $34.5 million in 2020, then slumped by 36.27% to $22.0 million in 2021, then slumped by 93.58% to $1.4 million in 2023, then sank by 98.23% to $25000.0 in 2024.
- The last three Total Non-Current Liabilities figures came in at $25000.0 (Q2 2024), $1.4 million (Q1 2024), and $1.4 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 25,000.00 |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 6.46 Mn |
| Jun 30, 2023 | 6.39 Mn |
| Mar 31, 2023 | 7.53 Mn |
| Sep 30, 2021 | 21.98 Mn |
| Jun 30, 2021 | 58.64 Mn |
| Mar 31, 2021 | 55.81 Mn |
| Dec 31, 2020 | 34.48 Mn |
| Sep 30, 2020 | 34.98 Mn |
| Jun 30, 2020 | 35.08 Mn |
| Mar 31, 2020 | 34.41 Mn |
| Dec 31, 2019 | 34.26 Mn |
| Dec 31, 2018 | 9.54 Mn |
| Sep 30, 2018 | 8.06 Mn |
| Jun 30, 2018 | 8.65 Mn |
| Mar 31, 2018 | 14.76 Mn |
| Dec 31, 2017 | 14.55 Mn |
| Dec 31, 2016 | 12.43 Mn |